A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers

• ClinicalTrials.gov Identifier: NCT05025072
• Recruitment Status: Completed
• First Posted: August 27, 2021
• Last Update Posted: October 7, 2021
• Sponsor: ADDMEDICA SASA
• Collaborators: Simbec Orion; Oncodesign SA; PHINC DEVELOPMENT
• Information provided by (Responsible Party): ADDMEDICA SASA

Tracking Information

• First Submitted Date: August 5, 2021
• First Posted Date: August 27, 2021
• Last Update Posted Date: October 7, 2021
• Actual Study Start Date: August 22, 2021
• Actual Primary Completion Date: September 29, 2021 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 23, 2021)

• Cmax [ Time Frame: 24 hours ]
  The observed maximum concentration (Cmax) in plasma
• AUC0-t [ Time Frame: 24 hours ]
  The area under the plasma concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration (t)
• AUC0-infinity [ Time Frame: 24 hours ]
  The AUC from time 0 to infinity

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: August 23, 2021)

• tmax [ Time Frame: 24 hours ]
  The time at which Cmax is apparent
• t1/2 [ Time Frame: 24 hours ]
  The terminal elimination half-life
• ke [ Time Frame: 24 hours ]
  The terminal elimination rate-constant
• AUC%extra [ Time Frame: 24 hours ]
  % of AUC0-infinity extrapolated
• Adverse events [ Time Frame: 24 hours ]
  Incidence of Adverse Events

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers
• Official Title: A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers

Brief Summary

This study is a Phase I, open-label, single-centre, randomised, two-period, single-dose crossover study to compare and assess the bioequivalence, safety, tolerability and pharmacokinetics of hydroxycarbamide dispersible tablets (20 x 50 mg) (test IMP) and Siklos® film-coated tablet (1000 mg) (reference IMP) following single-dose administration. Thirty (30) healthy male and female participants, between 18 and 50 years of age are planned to participate in the study.

Study participants will be randomised to one of the 2 possible combination sequences. After each treatment administration, blood samples will be collected at specific time points to assess the Pharmacokinetics (PK) parameters.

• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: None (Open Label); Primary Purpose: Other
• Condition: Healthy Volunteers

Intervention

• Drug: Hydroxycarbamide dispersible tablets
  Hydroxycarbamide dispersible tablets (20 x 50 mg)
• Drug: Hydroxycarbamide film-coated tablet
  Hydroxycarbamide film-coated tablet (1000 mg)

Study Arms

• Experimental: Test IMP
  Hydroxycarbamide dispersible tablets (20 x 50 mg)
  Interventions:

  • Drug: Hydroxycarbamide dispersible tablets
  • Drug: Hydroxycarbamide film-coated tablet
• Active Comparator: Reference IMP
  Hydroxycarbamide film-coated tablet (1000 mg)
  Interventions:

  • Drug: Hydroxycarbamide dispersible tablets
  • Drug: Hydroxycarbamide film-coated tablet

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: October 6, 2021): 28
• Original Estimated Enrollment (submitted: August 23, 2021): 30
• Actual Study Completion Date: September 29, 2021
• Actual Primary Completion Date: September 29, 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Healthy male and female participants, between 18 and 50 years of age, inclusive.
2. Female participant of childbearing potential willing to use a highly effective method of contraception, if applicable from the first dose until 3 months after the last dose of IMP.
3. Female participant of non-childbearing potential. For the purposes of this study, this is defined as the participant being amenorrhoeic for at least 12 consecutive months or at least 4 months post-surgical sterilisation.
4. Female participant with a negative pregnancy test at Screening.
5. Male participant (and partner of child bearing potential) willing to use a highly method of contraception, if applicable from first dose until 3 months after last dose of IMP.
6. Participant with a BMI of 18-29.9 kg/m2.
7. No clinically significant history of previous allergy / sensitivity to hydroxycarbamide or any of the excipients contained within the IMP(s).
8. No clinically significant abnormal test results for serum biochemistry, haematology and/or urine analyses within 28 days before the first dose administration of the IMP.
9. Participant with a negative urinary DOA screen (including alcohol) test results, determined within 28 days before the first dose administration of the IMP.
10. Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCV Ab) test results at Screening.
11. No clinically significant abnormalities in 12-lead ECG determined within 28 days before the first dose of IMP.
12. No clinically significant abnormalities in vital signs determined within 28 days before the first dose of IMP.
13. Participant must be available to complete the study.
14. Participant must satisfy an Investigator about his/her fitness to participate in the study.
15. Participant must provide written informed consent to participate in the study.

Exclusion Criteria:

1. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.
2. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 28 days or 5 half-lives prior to the first dose of IMP.
3. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction.
4. A clinically significant history of drug or alcohol abuse within the past two years.
5. Inability to communicate well with the Investigators.
6. Participation in a New Chemical Entity clinical study within the previous 3 months or five half-lives whichever is the longest, or a marketed drug clinical study within the 30 days or five half-lives whichever is the longest, before the first dose of IMP.
7. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.
8. Users of nicotine products i.e., current smokers or ex-smokers who have smoked within 6 months prior to Screening or users of cigarette replacements
9. Female participants who are pregnant, breastfeeding or lactating.
10. Participants who have received any live or attenuated vaccine within 28 days of the first dose of IMP, or who are planning to receive a vaccine up to 28 days after receiving the last dose of IMP in Treatment Period 2.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 50 Years (Adult)
• Accepts Healthy Volunteers: Yes
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United Kingdom

Administrative Information

• NCT Number: NCT05025072
• Other Study ID Numbers: SIK-FR-21-1
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: ADDMEDICA SASA
• Original Responsible Party: Same as current
• Current Study Sponsor: ADDMEDICA SASA
• Original Study Sponsor: Same as current

Collaborators

• Simbec Orion
• Oncodesign SA
• PHINC DEVELOPMENT

Investigators

• Principal Investigator: Annelize Koch, MD; Simbec Orion

• PRS Account: ADDMEDICA SASA
• Verification Date: October 2021